In the last trading session, 9.67 million shares of the Pacific Biosciences of California Inc (NASDAQ:PACB) were traded, and its beta was 2.13. Most recently the company’s share price was $1.30, and it changed around -$0.08 or -5.80% from the last close, which brings the market valuation of the company to $390.11M. PACB currently trades at a discount to its 52-week high of $2.72, offering almost -109.23% off that amount. The share price’s 52-week low was $0.85, which indicates that the current value has risen by an impressive 34.62% since then. We note from Pacific Biosciences of California Inc’s average daily trading volume that its 10-day average is 9.47 million shares, with the 3-month average coming to 8.68 million.
Pacific Biosciences of California Inc stock received a consensus recommendation rating of Hold, based on a mean score of 2.21. If we narrow it down even further, the data shows that 0 out of 14 analysts rate the stock as a Sell; another 1 rate it as Overweight. Among the rest, 8 recommended PACB as a Hold, whereas 5 deemed it a Buy, and 0 rated it as Underweight.
Pacific Biosciences of California Inc (NASDAQ:PACB) trade information
Instantly PACB has showed a red trend with a performance of -5.80% at the end of last trading. The performance over the last five days has remained in the green territory. The rise to weekly highs of 1.4000 on recent trading dayincreased the stock’s daily price by 7.14%. The company’s shares are currently down -28.96% year-to-date, but still up 12.07% over the last five days. On the other hand, Pacific Biosciences of California Inc (NASDAQ:PACB) is 25.60% up in the 30-day period. We can see from the shorts that 52.02 million shares have been sold at a short interest cover period of 5.55 day(s).
The consensus price target as assigned by Wall Street analysts is $3, which translates to bulls needing to increase their stock price by 56.67% from its current value. Analyst projections state that PACB is forecast to be at a low of $2 and a high of $4.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -23.55%. Pacific Biosciences of California Inc earnings are expected to increase by 6.60% in 2025, but the outlook is positive 27.48% per year for the next five years.
PACB Dividends
Pacific Biosciences of California Inc’s next quarterly earnings report is expected to be released on 2025-May-07.
Pacific Biosciences of California Inc (NASDAQ:PACB)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 9.06% of Pacific Biosciences of California Inc shares, and 66.08% of them are in the hands of institutional investors. The stock currently has a share float of 72.67%. Pacific Biosciences of California Inc stock is held by 308.0 institutions, with ARK INVESTMENT MANAGEMENT LLC being the largest institutional investor. By 2024-06-30, it held 12.1932% of the shares, which is about 33.21 million shares worth $45.5 million.
VANGUARD GROUP INC, with 9.5449% or 26.0 million shares worth $35.62 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
